Goal of the analysis:
Quantify patent application filings over time and by segment to understand the health of the innovation pipeline, align filings with business strategy and markets, and optimize cost and portfolio quality. For executives, Patent Filing Count is a leading indicator of IP creation and competitive differentiation. The analysis clarifies first-filings (new inventions) versus follow-on filings (continuations/divisionals), jurisdictional coverage versus revenue footprint, and conversion from invention disclosures to filings. It supports budgeting, outside counsel allocation, and strategic decisions on where to file and when to use PCT to preserve options.
Data required:
- IP docketing and management data:
- Application numbers, filing dates, application types (provisional, utility, design, PCT, continuation, divisional, CIP), priority dates and numbers, family IDs.
- Jurisdictions (USPTO, EPO, CNIPA, JPO, etc.), national phase entries and dates, current status (filed, published, abandoned, granted).
- Attorney/agent, outside counsel, internal owner, inventors, technology domain/classification (IPC/CPC), business unit/product mapping.
- Invention disclosure and pipeline:
- Disclosure IDs, submission dates, topics, inventors, triage decisions, prior art searches, committee decisions, expected filing paths.
- Disclosure-to-filing conversion dates; backlog of approved-but-not-filed disclosures.
- Financial and normalization bases:
- R&D spend by BU/region, headcount of R&D and engineering, revenue by region/market.
- Outside counsel rate cards and filing budgets (for cost-per-filing overlays).
- External patent data (optional but recommended):
- Public databases (WIPO PATENTSCOPE, EPO, USPTO) for validation of filings, publication lags, and competitor context.
- Citations and technology class trends to contextualize quality (used as overlays, not primary in filing count).
- Systems and references:
- IPMS/docketing tools (Anaqua, CPA Global/Clarivate, Patsy, FoundationIP), disclosure portals, PLM/R&D tools, finance systems.
- Taxonomy of technology domains, BU/region master data, product roadmaps.
Detailed step-by-step instruction on how to conduct the analysis:
- Define scope and counting rules.
- Period: rolling 12–24 months plus 3–5 years of history for trend analysis.
- Counting basis:
- Families vs applications: report both. “First-filings” (priority-starting events: provisional, non-provisional, PCT) indicate new inventions. “Total applications” include continuations, divisionals, CIPs, designs, and national phase entries.
- PCT handling: count PCT at international filing; count national phase entries separately at entry date.
- Jurisdiction duplicates: each application per jurisdiction counts once; link to its family.
- Extract and unify data.
- Export filings from IPMS with application type, dates, jurisdiction, family ID, inventors, BU/product mapping, and status.
- Pull invention disclosures and decisions; join to filings via disclosure ID or inventor/topic matching.
- Integrate R&D spend and headcount by BU/region; standardize technology domains (CPC/IPC to internal taxonomy).
- Cleanse and classify.
- Normalize application type labels (e.g., “CONT,” “DIV,” “CIP,” “PCT”) and confirm priority chains (earliest priority date per family).
- Resolve duplicates across system migrations; validate key dates (no national entry before PCT filing).
- Tag filings as First-Filing vs Follow-On; tag strategic importance (core product, platform, defensive).
- Compute core metrics.
- Total Filings (applications) per period; First-Filing Count (families started) per period.
- Provisional → Non-provisional Conversion Rate and median days from disclosure to filing.
- PCT Utilization Rate = PCT filings / First-filings; National Phase Entry Rate by jurisdiction.
- Continuation/Divisional Share = follow-ons / total applications.
- Jurisdiction Mix: % by US, EP, CN, JP, KR, etc.; alignment to revenue/market footprint.
- Normalized Filings: per $100M R&D spend; per 100 R&D employees.
- Disclosure-to-Filing Conversion = filings initiated / disclosures submitted (lag-adjusted).
- Segment and analyze.
- By BU/product line, technology domain, jurisdiction, outside counsel, inventor team/site.
- By strategic category (offensive/core vs defensive), and by application type (utility vs design).
- Map filings to product roadmap milestones and launch geographies.
- Trend and cohort perspectives.
- Quarterly trend of First-filings vs Total applications; rolling 12-month view to smooth seasonality.
- Cohorts by disclosure quarter: conversion to filings within 3/6/12 months; time-to-file distributions.
- PCT cohorts: share entering national phase within 30 months; jurisdictional split over time.
- Quality and cost overlays (optional but valuable).
- Early quality proxies: internal search completeness, claim breadth scoring, independence from existing families.
- Downstream indicators (lagging): grant rate and first office action outcomes for recent cohorts; citations received vs art unit norms.
- Cost per Filing and cost per Family start; outside counsel variance by firm/jurisdiction.
- Validate with stakeholders.
- Review anomalies (spikes, unusual jurisdiction mix) with R&D and IP counsel; reconcile missing disclosure links.
- Confirm strategic rationale for high continuation shares or low PCT usage in global businesses.
- Set targets and thresholds.
- Define annual targets for First-filings by BU/technology; set PCT usage policies by market strategy and budget.
- Set SLA: disclosure-to-filing decision ≤45–60 days; provisional conversion within 12 months with quality gate.
- Institutionalize reporting cadence.
- Quarterly executive dashboard; monthly operational reviews with IP committee and R&D leads.
Format of the output of analysis:
- Executive summary: First-filings vs Total applications, PCT utilization, continuation share, jurisdiction mix, normalized filings per $100M R&D and per 100 R&D FTE.
- Trend charts (quarterly) for First-filings and Total applications; disclosure-to-filing conversion funnels.
- Heatmaps by BU/product/technology and by jurisdiction; alignment to revenue/launch markets.
- Cohort views for provisional conversions and PCT national phase entries.
- Outside counsel scorecards: volume by firm, cost per filing, timeline adherence.
- Appendix: counting rules (family vs application), PCT/national phase treatment, taxonomy, data sources.
How to interpret results:
- Rising First-filings indicate a growing innovation pipeline; rising Total applications driven mostly by continuations may inflate counts without adding new inventions—balance is key.
- Low PCT usage in globally marketed products suggests under-protection; conversely, high PCT share without national entries may indicate indecision or budget hold.
- Jurisdiction mix should correlate with revenue footprint, manufacturing locations, and competitor activity; significant misalignment merits review.
- Slow disclosure-to-filing conversion risks public disclosure conflicts and loss of rights; faster cycles with quality gates are preferred.
- Normalized filing rates (per R&D spend/headcount) enable fair BU comparisons; outliers can reflect differing IP strategies (trade secret preference) or capability gaps.
- High design filing share is appropriate for aesthetic-driven products; for deep-tech, utility filings should dominate.
Steps a company can take to improve on this measure:
- Process and governance:
- Implement an invention disclosure portal with clear triage SLAs and a cross-functional IP committee meeting biweekly.
- Establish quality gates: prior art search and business case before filing; standard templates and claim guidelines.
- Define PCT and jurisdiction selection policy aligned to product launch plans and competitor geographies.
- Data and systems:
- Consolidate to a single IPMS as system of record; enforce family IDs and disclosure linkages.
- Create dashboards linking filings to R&D projects, spend, and headcount; automate cohort/normalization metrics.
- Capability and culture:
- Train engineers and product managers on patentability, disclosure hygiene, and timing relative to publications/launches.
- Run invention harvesting workshops near key roadmap milestones; recognize inventors and managers.
- Portfolio and cost management:
- Use PCT to defer and optimize national filings; prioritize top markets; cull low-value continuations.
- Standardize outside counsel engagement with fixed-fee menus and jurisdictional playbooks; benchmark cost per filing.
- Scenario guidance:
- If First-filings are flat but disclosures rise: fix triage bottlenecks, add search capacity, and clarify criteria.
- If continuation share is high: review prosecution strategy; consolidate claims; avoid unnecessary follow-ons.
- If PCT conversion to national phase is low: tighten business case gates at 18–24 months and reduce speculative PCT filings.
Benchmark comparisons:
General benchmarks:
- Normalized filing intensity (very directional; varies by industry and strategy):
- Filings per $100M R&D: roughly 20–80 total applications; First-filings (families) often 10–30.
- Filings per 100 R&D FTE: roughly 5–20 total applications; First-filings 3–10.
- Portfolio mix:
- PCT Utilization among globally oriented portfolios: 30–70% of First-filings.
- Continuation/Divisional share: 20–50% of total applications in prosecution-heavy portfolios.
- Jurisdiction mix: US and EP commonly 50–80% combined for Western-focused portfolios; add CN/JP/KR for Asia strategies.
Segment- or industry-specific benchmarks:
- Software/electronics: higher filing velocity; filings per $100M R&D often on the higher end; extensive US/EP/CN coverage.
- Industrial/automation: mid-range filing intensity; strong protection in US/EP/JP; designs used for product look-and-feel.
- Medtech/pharma diagnostics (device-heavy): moderate filing volume with higher quality thresholds; PCT widely used; fewer but more valuable families.
- Consumer goods: mix of utility and design filings; broader jurisdictional spread aligned to manufacturing and sales regions.
Where external benchmarks are not directly comparable, construct internal ones: set a 3–5 year baseline of First-filings and Total applications by BU/technology; normalize per R&D spend and headcount; target top-quartile internal performers; and track mix (PCT usage, continuation share) and conversion from disclosures alongside counts. Refresh targets annually to reflect strategy shifts and budget.
